Descriptive Observational Study ALK-2016-CPHG

Inclusion Criteria

• •Age ≥ 18 years
• •Locally advanced or metastatic NSCLC
• •Patient ALK gene rearrangement or ROS1 gene rearrangement
• •Patient having initiated in the previous 3 months or patient initiating crizotinib treatment regardless of the line of treatment
• •Patient followed up by a physician in a hospital pulmonary medicine department
• •Subject of reproductive age, using an effective method of contraception
• •Patient informed verbally and in writing on the study and having consented to his/her personal data being collected within the scope of the study.
• •Patient included within the scope of an interventional therapeutic trial
• •Patient not presenting with ALK gene rearrangement or ROS1 gene rearrangement
• •Patient not available for follow-up throughout the duration of the study
• +1 more criteria